The drug pricing debate has moved in some unexpected directions in the US over the past two years.
For the most part, the biopharma industry has been successful in focusing attention on the difference between list and net...
PBMs Play Outsized Role … In Hearing On Health Sector Consolidation
PBMs have become a central focus of the drug pricing debate, thanks in large part to the biopharma industry’s efforts to shine a spotlight on the role of rebates and middlemen in consumer costs. They were also a surprising focus on a hearing about health industry consolidation.
